SCHEMBL4922786

SCHEMBL4922786

CCOC(=O)c1cc2cc(Oc3ccc(C(C)(C)C)cc3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.62
NR1H4 Q96RI1 1/20 0.39
PPARG P37231 6/20 0.38
PPARA Q07869 3/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
LGALS8 O00214 1/20 0.36
LGALS3 P17931 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
GCGR P47871 1/20 0.36
GALR3 O60755 1/20 0.36
GAA P10253 1/20 0.36
THRB P10828 1/20 0.35
MAOB P27338 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009731 0.91 PTGES (0.52) PTGESPPARGPPARAMAPTTP53
SCHEMBL3578959 0.90 PTGES (0.77) PTGESNR1H4PPARGPPARACYP2C9
SCHEMBL4920933 0.88 PTGES (0.48) PTGESMAPTTP53LGALS8LGALS3
SCHEMBL4925712 0.87 PTGES (0.81) PTGESNR1H4PPARGPPARASMN1; SMN2
SCHEMBL2997482 0.84 PTGES (0.50) PTGESPPARGMAPTTP53SMN1; SMN2
SCHEMBL4224238 0.84 PTGES (0.45) PTGESCYP2C9CYP2C19TP53LGALS8
SCHEMBL3001458 0.83 PTGES (0.51) PTGESPPARGMAPTTP53SMN1; SMN2
SCHEMBL3575712 0.83 PTGES (0.64) PTGESPPARGMAPTTP53SMN1; SMN2
SCHEMBL4228507 0.82 SCN9A (0.48) PTGES
SCHEMBL3578734 0.82 PTGES (0.50) PTGESPPARGMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249091-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249091-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, ARG1 PTGES 35/4885NR1H4 908/4885PPARG 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.